

REVIEW



The regulatory role of Toll-like receptors after ischemic stroke: neurosteroids as TLR modulators with the focus on TLR2/4

Saeedeh Tajalli-Nezhad¹ · Mohammad Karimian¹ · Cordian Beyer² · Mohammad Ali Atlasi¹ · Abolfazl Azami Tameh¹

Received: 8 April 2018 / Accepted: 19 October 2018
© Springer Nature Switzerland AG 2018

Abstract

Ischemic stroke is the most common cerebrovascular disease and considered as a worldwide leading cause of death. After cerebral ischemia, different pathophysiological processes including neuroinflammation, invasion and aggregation of inflammatory cells and up-regulation of cytokines occur simultaneously. In this respect, Toll-like receptors (TLRs) are the first identified important mediators for the activation of the innate immune system and are widely expressed in glial cells and neurons following brain trauma. TLRs are also able to interact with endogenous and exogenous molecules released during ischemia and can increase tissue damage. Particularly, TLR2 and TLR4 activate different downstream inflammatory signaling pathways. In addition, TLR signaling can alternatively play a role for endogenous neuroprotection. In this review, the gene and protein structures, common genetic polymorphisms of TLR2 and TLR4, TLR-related molecular pathways and their putative role after ischemic stroke are delineated. Furthermore, the relationship between neurosteroids and TLRs as neuroprotective mechanism is highlighted in the context of brain ischemia.

Keywords Ischemic stroke · Neurosteroids · Toll-like receptors

Introduction

Stroke resulting from focal occlusion of a main artery in the brain is considered as the most important cause of disability in men and a leading cause of death worldwide. Initial damage after the primary ischemic event is followed by delayed metabolic alterations called secondary injury mechanisms which can increase excitatory neurotransmitter levels, neuronal apoptosis, immune-inflammatory activation as well as lipid degradation [1–3]. In this respect, systemic and local inflammatory responses play a main role in the pathophysiology of cerebral ischemia. The given responses can similarly not only increase the ischemic lesion but also protect injured tissue [4, 5]. Macrophages, neutrophils, and lymphocytes have equally distinct significant roles in different brain inflammatory events even though the underlying mechanisms leading to their activation are not fully

clear. Toll-like receptors (TLRs) are activated in response to inflammation and are also recognized as innate immune receptors located on the cell surface or inside endosomes [4, 6]. Activation of TLRs leads to the initiation of different downstream inflammatory cascades. TLR expression can also be regulated in response to exogenous microorganisms as well as different types of cytokines (chemokines, interferons, and interleukins) which are secreted in the core and the penumbra region of ischemic brain tissue [7, 8]. Expression of these mediators depends on nuclear factor- κ B (NF- κ B) as the main transcription factor implicated in the TLR pathway [8]. Therefore, these receptors may have an important role mediating brain damage following ischemia and are thus assumed as clinical targets for preventing secondary injury after ischemic stroke [9, 10]. In this review article, we focus on the TLR family and their respective ligands, structures, and signaling pathways and also point at the role of TLRs in ischemic stroke emphasizing the interaction with neurosteroids. Moreover, gene and protein structures as well as common genetic polymorphisms of TLR2 and TLR4 molecules and their possible roles in stroke-induced inflammatory pathways are discussed. Finally, the relationship between neurosteroids and TLRs following an ischemic event in the brain is underlined as therapeutic targets for stroke therapy.

✉ Abolfazl Azami Tameh
aazami@kaums.ac.ir

¹ Anatomical Sciences Research Center, Kashan University of Medical Sciences, Kashan, Iran

² Institute of Neuroanatomy, Faculty of Medicine, RWTH Aachen University, Wendlingweg 2, 52074 Aachen, Germany

TLR family and expression

TLRs are a family of molecules playing a major role in the innate immune system [11]. TLR inflammatory responses and cytokine secretion typically increase in glial cells and leukocytes in response to microorganisms [12]. A total number of 13 TLRs have been identified until now, of which only 10 (TLR1–10) have been related to humans [13]. Generally, TLR localization and expression depends on the tissue or cell type. TLR1, 2, 4, 5, 6, and 10 are localized on the cell surface, whereas TLRs 3, 7, 8, and 9 are usually expressed exclusively in intracellular compartments such as endosomes and lysosomes [14, 15]. Based on their sequence homologies, human TLRs can be grouped into five subfamilies of TLR1/2/6/10, TLR3, TLR4, TLR5, TLR7/8/9 [16, 17]. TLRs have also been described as prototype pattern recognition receptors (PRRs) and are able to recognize danger-associated molecular patterns (DAMPs) or pathogen-associated molecular patterns (PAMPs) which are released from damaged tissue or microorganisms [18, 19]. It should be noted that DAMPs are released or modified and then bound to their respective receptors after an inflammatory response. DAMPs can also include extracellular matrix fibronectin, hyaluronan, heparin sulfate, and even molecules which are found in intracellular compartments such as ATP, heat-shock proteins, uric acid, and those of nuclear origin such as high mobility group box 1 protein (HMGB1), double-strand RNA (dsRNA), single-strand RNA (ssRNA), DNA, and microRNAs [19, 20]. PAMPs which are recognized by TLRs and derived from bacteria, viruses, parasites, and fungi include lipids, lipoproteins, proteins as well as nucleic acids [21]. In this regard, TLRs on the cell surface are capable to identify PAMPs as their ligands, e.g., TLR1/TLR2, TLR2/TLR6, and TLR4. TLR4 is considered as a receptor for lipopolysaccharide (LPS) and myeloid differentiation factor 2 (MD2), and TLR5 binds to flagellin. Intracellular TLRs include TLR3 which recognizes microbial nucleic acid including viral dsRNAs, TLR7, and TLR8 which can interact with ssRNAs, and TLR9 which binds to CpG-containing DNA [22]. TLRs are expressed in glial cells (microglia, astrocytes, oligodendrocytes), neurons in the central nervous system (CNS) and peripheral nervous system (PNS) [23–25]. Likewise, they are often found in circumventricular organs and meninges with direct access to the circulation. TLRs also exist on antigen-presenting cells (APCs) in the CNS such as dendritic cells, B cells, macrophages, microglia, monocytes, and endothelial cells [26, 27]. Thus, the presence of specific TLRs in microglia and astrocytes allows to respond in different manner. For instance, microglia can secrete vigorous chemokines and cytokines in response to TLR 2, 3, 4 stimulation, whereas astrocytes can secrete low IL-6 levels in response to a stimulation with TLR3 [26].

Structurally, TLRs are categorized as type I integral membrane glycoproteins that share a common domain structure consisting of an extracellular recognition domain, a single transmembrane domain (helix), as well as an intracellular Toll-interleukin 1 receptor (TIR) homology signaling domain [28, 29]. The extracellular domains encompass leucine-rich repeats and mediate the recognition of PAMPs, the transmembrane domain and the intracellular TIR domains are also essential for triggering downstream signaling pathways [15, 30]. The N-terminal ectodomains of TLRs are glycoproteins with 550–800 amino acids and are located in the extracellular region or appear in the lumen of endosomes, wherein they can recognize molecules secreted by invading pathogens [31].

Expression of TLR2 in innate immune cells appears differentially regulated by inflammatory mediators. TLR2 levels in monocytes are increased by IL-1, IL-10, and LPS, and decreased by TNF, IL-4, and IFN- γ . TLR2 expression in purified granulocytes is also down-regulated by LPS and TNF, but strongly up-regulated by IL-10 [32]. Interestingly, studies investigating the expression of TLR2 in cultured mouse astrocytes were consistent in this respect, whereas other reports in other cell systems are contradictory. For example, Bsibsi et al. suggested the presence of TLR2 mRNA in human astrocytes, whereas Farina et al. were unable to discover this molecule [33, 34]. Moreover, cytokine- or LPS-activated mouse brains showed TLR2 expression in microglia but not in astrocytes [35, 36]. Besides, expression of TLR2 is found in primary human oligodendrocytes [33], though the functional importance of TLR2 in this cell type is unclear.

In vitro or in vivo expression of astrocytic TLR4 also appears controversial. Reports have revealed that cultured astrocytes require microglia to entirely respond to LPS in vitro. Furthermore, oxygen–glucose deprivation in mixed glial cultures comprising astrocytes and microglia induces expression of TLR4 in these cells. TLR4 expression was much lower in astrocytes than in microglia [37–39]. However, one study reported that TLR4 was expressed in astrocytes but at just a comparatively low ratio compared to microglia [38]. It was additionally examined whether pro-inflammatory agents including LPS or IL-1 β could modify TLR4 expression in microglia and astrocytes. Neither LPS nor IL-1 β significantly affected the expression of TLR4 in astrocytes. In contrast, TLR4 expression in microglia was up-regulated by IL-1 β but unaffected by LPS [40].

TLR signaling pathways

Pro-inflammatory cytokines and chemokines are considered as the final products of the TLR signaling pathway [41]. A total number of five different adaptor molecules are described

for TLRs: the myeloid differentiation primary response gene 88 (MyD88), MyD88 adaptor-like protein (MAL), TIR-domain-containing adaptor protein including interferon- β -mediated transcription factor (TRIF), TRIF-related adaptor molecule (TRAM), and sterile- α and armadillo motif-containing protein (SARM) [42]. These adaptor molecules are considered as recruiters for the initiation and stimulation of downstream kinases and transcription factors that are involved in inflammation and antiviral responses [43]. TLRs and their respective adaptors can also interact with the homologous TIR domains present in both TLRs and adaptor molecules. Based on the recruitment of particular adaptors, TLRs can thus converge on two second messenger pathways: MyD88 dependent or MyD88 independent. Basically, MyD88 adaptor protein can activate signals of the MyD88-dependent pathway with all TLR family members involved with the exception of TLR3 [22, 44]. TLR1/2/4/6 is also bound to MyD88 after successfully assembling with TIRAP/Mal [45, 46] and then, MyD88 can activate the IL-1 receptor-associated kinase 4 (IRAK4). Moreover, MyD88 can recruit other members of the IRAK family, such as IRAK-1 that stimulates mitogen-activated protein kinase and the NF- κ B pathway (Fig. 1) [47]. Formation of MyD88 and IRAKs complexes are likely to disassociate and react with tumor necrosis factor receptor-associated factor 6 (TRAF6). TRAF6 together with an ubiquitin-conjugating enzyme 13 (Ubc13) and ubiquitin-conjugating enzyme E2 variant 1 (Uev1A) can catalyze Lys-63 (K63)-linked polyubiquitination which initiates the activation of a complex consisting of transforming growth factor- β -activated kinase (TAK1), TAK1-binding protein 1 (TAB1), and TAB2 leading to phosphorylation of TAK1 and TAB2/3 [48, 49]. As well, TAK1 activates the inhibitor of NF- κ B (I κ B)–kinase complex (IKK) which is composed of IKK- α , IKK- β , and IKK- γ (Fig. 1). This complex phosphorylates I κ B and causes NF- κ B dissociation and translocation to the nucleus and the subsequent pro-inflammatory cytokine gene expression such as interleukin 1 β (IL-1 β), IL-6, and tumor necrosis factor- α (TNF- α) [22, 50]. NF- κ B consists of p65 and p50 dimers that are inactive if present in the cytoplasm in association with I κ B [51]. The second part of the TAK1 pathway is the activation of mitogen-activated protein kinases (MAPKs) which includes three families of p38 MAPKs, extracellular signal-regulated kinases (ERKs), and c-Jun-N-terminal kinases (JNKs). Finally, MAP kinase is responsible for the formation of AP-1, another transcription factor complex inducing cytokine gene expression (Fig. 1) [50, 52, 53].

TLR4 is the only member of the TLR family that is able to trigger both MyD88- and TRIF-dependent signaling pathway-related genes [44]. LPS is considered an important ligand which binds to TLR4 and leads to endosome formation resulting in TRAM translocation to cytosol and TRIF-dependent signaling pathway activation [50]. This pathway responds with TRAF3 expression and activation of

the TANK-binding kinase/I κ B kinase (TBK1/IKKi) complex which leads to the interferon regulatory factor (IRF), IRF3 and IRF7, phosphorylation. The phosphorylated IRF3 and IRF7 dimer will then translocate to the nucleus and finally induce IFN gene expression [22, 45, 50]. TRAF6 is another target after TRIF downstream activation pathway which is activated by receptor interacting protein 1 (RIP1) followed by TAK1 complex and NF- κ B (Fig. 1) [46, 49].

As well, suppressor of cytokine signaling (SOCS1) is known as a protein induced by cytokines and can negatively regulate cytokine-signaling pathway and directly down-modulate the TLR-signaling pathway [54, 55]. SOCS1 also affects the TLR–NF- κ B pathway and binds to the p65 subunit of NF- κ B to help ubiquitylation of p65. SOCS1 might regulate stress-activated MAPKs and finally lead to the suppression of MAL-dependent p65 phosphorylation and NF- κ B transactivation [56, 57].

Moreover, a molecule family termed triggering receptors expressed on myeloid cells (TREM) can influence the downstream signaling pathway of the TLRs. TREM molecules have both activating and inhibitory receptors as regulatory factors playing a role in TLR-mediated inflammatory responses [58]. TREM-1 and TREM-2 can act on immune cells involved in innate immune responses. It was reported that TREM-1 expression increases during an infection in vivo and following TLR stimulation in vitro [59, 60]. Silencing of TREM-1 influences chemokine and cytokine production by elevating access to downstream signaling molecules involved in acute inflammation. This silencing did not change TRIF-mediated expression of INF indicating that TREM-1 has no main role in reinforcing this TLR signaling pathway. However, the influence of TREM-1 silencing on CD14, MyD88, and other molecules in downstream signaling suggests reduced pro-inflammatory signaling. These authors also noted significant reductions in MyD88 and CD14 transcripts as well as in downstream molecules of the NF- κ B pathway following LPS stimulation in the setting of TREM-1 silencing [61, 62]. The overexpression of surface-associated TREM-1, TLR2, and TLR4 in CD14^{hi}CD16⁺ monocytes approves this pro-inflammatory role. However, simultaneous stimulation of TREM-1 and TLRs induced synergistically cytokine production and amplified inflammatory signals [63]. TREM-2 exists in naive primary astrocytes and was induced by exposure with LPS, OGD, or HMGB-1. Thus, the activation of TREM-2, overexpression of DAP12, and intracellular adaptor of TREM-2 could partly inhibit the activation of NF- κ B induced by LPS in purified astrocytic cultures. Expression of TLR4 could also increase the sensitivity of astroglial cells to ligands, thereby facilitating an astrocyte shift towards a pro-inflammatory status. Then TREM-2 could moderate this response by decreasing downstream NF- κ B activation. Therefore, TREM-2 and TLR4 expressions in astrocytes might control the sensitivity of astrocytes to TLR ligands by regulation of downstream NF- κ B activation [39].




Fig. 1 TLR cell signaling pathways. TLR4 and the heterodimers of TLR2/TLR1 or TLR2/TLR6 located on the cell surface identify their respective ligands. TLR4 is the only member of the TLR family which is also located in endosomes. The intracellular TLRs, TLR3, TLR7, TLR8, TLR9 are also found in endosomes. Every TLR family member, except TLR3, uses the MyD88-dependent signaling pathway. TRAP/Mal adaptor proteins bridge MyD88 to TLR1/6/2/4 and promote their interactions with TRAF6. TRAF6 activates the complex of TAK1, TAB1, and TAB2/3. TAK1 activates both the IKK complex and MAPK. Complex of IKK which causes I κ B phosphorylation resulting in the translocation of NF- κ B to the nucleus where pro-inflammatory gene expression is triggered. p38, ERK,

JNK induced by MAPKs cause the AP-1 nuclear translocation. TLR 7/8 and 9 can activate MyD88 through two pathways: one pathway causes the translocation of IRF7 transcription factor to the nucleus and leads to type I IFN expression; the other pathway induces NF- κ B as a downstream signaling molecule. TRIF is another adaptor protein which is recruited by TLR3 and TLR4 independently from the MyD88 pathway and leads to IRF3/IRF7 dimer translocation to the nucleus resulting in the expression of type I IFN. Furthermore, TRIF can interact with TRAF6 through an effect on RIP-1 which is followed by NF- κ B activation. SOCS1 can inhibit the TLR signaling pathway via impact on NF- κ B and MAPK activity and phosphorylation of p65

TLRs and stroke

There is good evidence that TLRs and their ligands play an important role after brain ischemic injury. The inflammatory responses in immune cells are mediated by TLRs suggesting that these receptors contribute to induce ischemic damage. It is evident that resident cells such as astrocytes and microglia initiate the inflammatory cascades after

cerebral ischemia by recognizing injury-associated molecules. Subsequently, infiltration of immune cells such as macrophages and neutrophils to the damaged area take place and a massive release of inflammatory cytokines, proteolytic enzymes, and other cytotoxic mediators can be observed [7, 64, 65]. Several prospective studies including rodent models have investigated the function of TLRs in cerebral ischemia and addressed the basic question which

TLR subpopulations are essential for the progression of ischemic damage in the brain [66].

TLR2 has been shown to be involved in sterile inflammation like ischemic brain damage [66, 67]. TLR2 can also act on glial cells to secrete inflammatory factors and pro-inflammatory mediators which further propagate brain damage [68]. Recent studies have indicated that leukocyte infiltration into the damaged area via a disrupted blood–brain barrier (BBB) and the subsequent induction of apoptosis in neurons can be induced by TLR2 and reduced by TLR2 suppression [69]. TLR2 mRNA levels in resident microglia are increased following brain ischemia in mice [66]. Besides, TLR2 can bind to endogenous ligands after ischemic stroke [70, 71]. HMGB1, considered as an essential DAMP in ischemic damage, is localized in the cell nucleus and translocated into the cytosol after ischemic injury to stimulate TLR2. It has been reported that HMGB1 neutralizing antibodies reduce the infarct volume after MCAO [72–74]. Peroxiredoxin (Prx) family protein which is expressed in the injured area is another member of DAMPs with a neuroprotective role [75, 76]. Neurons of TLR2-deficient mice are also protected against cell death induced by an ischemia-like energy exclusion model. In addition, less CNS damage has been seen in TLR2-knockout mice following focal cerebral ischemia [66, 77]. Mice lacking TLR2 gene have shown less brain damage and neurological deficits after MCAO compared to wild-type mice revealing an up-regulation of TLR2 gene in the non-ischemic brain hemisphere [68, 77]. An up-regulation of the TLR2 gene has been also reported in an *in vitro* ischemia/reperfusion model in cultured microglia [78]. It should be noted that the activation of microglia occurs by the release of toxic cytokines such as IL-23 and IL-17 during ischemia/reperfusion. The inhibition of this pathway in microglia can result in a protection after ischemia. Besides, inflammatory signaling of TLR2 in the post-ischemic brain requires the scavenger receptor CD36. The lack of this receptor can suppress inflammation. These findings suggest that the TLR2–CD36 complex could act as a sensor of ischemia at the onset of death signals and is vital for the inflammatory responses [79]. Therefore, TLR2 suppression could be potentially considered as a future treatment for ischemic stroke [69]. Other members of the TLR family, *i.e.*, TLR3 or TLR9, also appear to be involved in brain ischemia [80–82]. For example, Alex *et al.* found that TLR3 signaling lowers the release of inflammatory cytokines by NF- κ B pathway suppression in TLR3-knockout mice [82–85]. TLR4 is considered to play a pivotal role for the progression of infarct volume in the ischemic brain via its binding to the endogenous ligands like HMGB1 which then causes immune cell infiltration through BBB into the infarct area and its surrounding regions [70, 71, 73, 81, 86–88]. TLR4 gene expression is increased in neurons after cerebral ischemia accompanied by the enhancement of multiple inflammatory cytokines. Knockout of the TLR4 gene in neurons can thus improve their

survival under glucose-deprived conditions [66]. This was also proven in TLR4-deficient mice which displayed less infarct volume compared to wild types [89–93]. Similarly, researchers revealed that TLR4-mutant mice had less expression of cyclooxygenase 2 (COX2), inducible nitric oxide synthase (iNOS), and IFN- γ [89, 90, 92]. Moreover, it was suggested that LPS as a ligand of TLR4 could modulate this receptor [68, 94]. It should be noted that TLR7 and 8 seem to be directly involved in inflammatory damage following ischemic stroke [80].

TLR2 and TLR4 are known to be more essential than other TLRs in the pathological development of ischemic brain damage [10]. Nalamolu *et al.* described the neuroprotective impact of simultaneous TLR2/TLR4 suppression under ischemic stroke conditions probably mediated by mitigating the induction of the pro-inflammatory cytokines TNF, IL-1, and IL-6 [95]. Therefore, TLR2 and TLR4 can be considered as interesting targets for stroke treatment. A better knowledge about the molecular structure, genetic variations, and modulation by several reagents of TLRs can help in future managing stroke prevalence and treatments.

TLR gene polymorphisms and stroke risk

There are reportedly several polymorphisms in TLR2 and TLR4 genes which may possibly change the risk for stroke. According to the National Center for Biotechnology Information (NCBI) database, many single nucleotide polymorphisms (SNPs) exist in TLR2 and TLR4 genes including rs5743708, rs1927911, rs4986790, and TLR4-C119A [96, 97]. TLR2 is located on chromosome 4 (4q31.3) with 5 exons and rs5743708 transition is situated on exon 5 [98]. This polymorphism, a missense mutation, can lead to a glutamine-to-arginine substitution at codon 735 (p.Arg753Gln). Besides, the rs1927911 variant is located on intron 1 of the TLR4 gene on chromosome 9 (9q33.1) [99]. Considered as a missense SNP, the rs4986790 is situated on exon 4 of TLR4 with the substitution of glycine to aspartate at codon 299 (p.Asp299Gly). In addition, the TLR4-C119A transversion is located on intron 1 of the TLR4 gene. Results from a previous study revealed that allele and genotype frequencies of rs1927911 were significantly different between stroke and control groups, while rs5743708 was not reported to be different between these groups. For rs1927911, it was shown that fasting blood glucose, blood pressure, and levels of serum lipids were not significantly different among the various genotypes in stroke and control groups [96]. Lin *et al.* reported a significant association between A119C polymorphism and stroke risk and demonstrated that the TLR4-119A allele might be a risk factor for ischemic stroke and it was also concluded that rs4986790 was a rare variation in the given study population [97].

Pathogenic effects of gene polymorphisms can be variable and depend on the position of SNP on the gene, RNA, and protein sequences [100, 101]. The four aforementioned SNPs may also influence molecular aspects of TLR2 and TLR4. As mentioned in (Table 1) and according to the RNAsnp database, only the rs4986790 polymorphism appeared to be deleterious for the TLR4 RNA structure [102]. This polymorphism could reduce the minimum free energy of RNA, change the expression of interested gene, and consequently change the expression of the genes of interest (Fig. 2) [103–105]. It should be noted that rs5743708 and rs4986790 polymorphisms are non-synonymous SNPs. Generally, non-synonymous polymorphisms cause amino acid substitutions in the protein sequence [106, 107]. According to the SNPeff database, rs5743708 transition is located in a helix region of TLR2, whereas the rs4986790 SNP is situated in an extended region of TLR4 protein (Fig. 3). In addition, the database records have predicted both rs5743708 and rs4986790

SNPs as harmful polymorphisms that are likely to reduce protein stability [108]. Other databases including PolyPhen-2 [109], SNAP [110], SIFT [111], and SNPeff [112] can also provide evidence that rs5743708 transition is deleterious. Despite the fact that PolyPhen-2, SIFT, PhD-SNP, and SNPs&GO [113] databases have predicted rs4986790 transition as a benign SNP for TLR4 molecule (Table 2), it could be concluded that damaging effects of rs4986790 could arise from alterations in TLR4 RNA structure, while harmful effects of rs5743708 were likely to be caused by changes in the protein structure of TLR2.

Neurosteroids as TLR modulators

Neurosteroids can be synthesized by both neurons and glial cells and act within CNS [114]. Neurosteroids synthesized by nervous tissue can act through their intracellular nuclear receptors thereby regulating gene expression [115]. Thus, they are able to protect the brain via an inhibition of TLR-related pathways from damage [116]. The risk of stroke in women typically increases at post-menopause stage indicating the protective potentials of female sex hormones, i.e., estrogen and progesterone (EP) [117]. Generally, both steroids are neuroprotective in the CNS under acute neurodegenerative and neuropathological conditions [118–121]. Animal and human studies have also shown that EP decreases post-stroke ischemic injury [122–125]. Vitamin D and its

Table 1 Effects of SNPs on RNA structure of TLR2 and TLR4

| SNP | Gene | Folding window | Local region | Distance | <i>p</i> value |
|-----------|------|----------------|--------------|----------|----------------|
| rs5743708 | TLR2 | 3085–3485 | 3261–3316 | 0.0009 | 0.9718 |
| rs1927911 | TLR4 | 8395–8795 | 8566–8615 | 0.0188 | 0.6715 |
| rs4986790 | TLR4 | 827–1227 | 972–1036 | 0.1510 | 0.1203 |
| C119A | TLR4 | 5208–5608 | 5399–5606 | 0.0422 | 0.5465 |

p values less than 0.2 are considered to be significant




Fig. 2 Secondary structure of RNA of human TLR4 before and after rs4986790 transition. Optimal secondary structure of global sequence (highlighted from 827 to 1227 nt) in the wild type with minimum

free energy = -129.20 kcal/mol (a) and mutant with minimum free energy = -74.60 kcal/mol (b). The figure was modified from rnaSNP




Fig. 3 Partial three-dimensional structures of TLR2 and TLR4. The rs5743708 and rs4986790 substitutions are a helix domain of TLR2 (**a**) and an extend domain of TLR4 (**b**), respectively

Table 2 Effects of rs5743708 and rs4986790 SNPs on protein structure

| SNP | Gene | Motif position | PolyPhen-2 | SNAP | SIFT | SNPeffect | PhD-SNP | SNPs&GO |
|-----------|------|----------------|------------|------|------|-----------|---------|---------|
| rs5743708 | TLR2 | Helix | + | + | + | + | + | – |
| rs4986790 | TLR4 | Extend | – | + | – | + | – | – |

The “+” and “–” symbols show deleterious and benign effects, respectively

metabolites are also recognized as important neurosteroids that are capable to guard neurons following ischemia [126–128].

Estrogen

This hormone exerts its biological actions mainly through three different estrogen receptors (ERs) including ER α , ER β , and G protein-coupled receptor 30 (GPR30) which are all expressed in the brain and linked to various molecular pathways such as membrane-linked receptors and nuclear receptors [129, 130]. The modulation of neuroinflammation is considered as one the most important neuroprotective mechanisms of estrogens after brain ischemia [131]. Accordingly, studies have shown that estrogen decreases toxic damage to neurons and regulates neuroinflammatory processes via the modulation of glial cell function, and consequently reduces infarct volume when it is given after permanent or transient brain ischemia [11, 132–136]. 17 β -Estradiol (E2) has been reported to suppress the release of cytokines and pro-inflammatory factors such as TNF- α , IFN- γ , and IL-17. Additionally,

E2 can promote the release of the anti-inflammatory factors such as transforming growth factor beta (TGF- β) and IL-10 [137, 138]. Generally, E2 plays an important role for the TLR/NF- κ B signaling pathway. It has been demonstrated that TLR4 is down-regulated by E2. Moreover, TLR2 is significantly down-regulated in ER α mutant ovariectomized mice [139, 140]. Additional studies have indicated the neuroprotective effects of ER α following experimental ischemic damage through the interaction of ER α with IL-6 and NF- κ B [141–145].

As mentioned above, E2 can act via ER α independent of its nuclear function by preventing NF- κ B nuclear translocation. This demonstrates that E2–ER α signaling pathways play an important role in immediate-early inflammatory response (Fig. 4a) [146]. E2 levels elevated in obesity and during pregnancy could also increase the expression of I κ B α as an anti-inflammatory molecule. On the other hand, ER β could block nuclear translocation of NF- κ B in cerebral ischemia [147]. Elevated levels of TLR2, TLR4, and MyD88 mRNA, activated NF- κ B, and also phosphorylated p65 in ovariectomized mice may be reversed by ER β agonists (Fig. 4a) [139]. Moreover, estrogen treatment could reduce the expression of TNF- α after cerebral ischemia,

although it has been reported that chronic administration of E2 stimulates TNF- α and pro-inflammatory cytokine release [148–150].

Pre-treatment of male rats with E2 in a MCAO model also showed a significant down-regulation of IL-1 β and a lowering of infarct volume compared to non-treated males [151]. There are other reports showing IL-6 inhibition and control of inflammation after E2 treatment in ischemic stroke [152]. Furthermore, E2 could boost the MAPK/ERK pathway which mediated neuroprotection and deprivation of this hormone modulates activation and expression of the p38 MAPK family members in the brain [153, 154]. In this respect, Koerner et al. revealed that estrogen replacement in ovariectomized mice could lead to temporal anti-inflammatory responses that were likely to induce immunosuppression [140]. Following brain ischemia, estrogen can also promote the formation of the resting microglia and astrocyte phenotype which reduce their activation, proliferation, and migration towards the damaged region and may be assumed responsible for the inhibition of glial-derived pro-inflammatory factors [122].

Progesterone

This neurosteroid appears to be neuroprotective in a variety of species including human particularly in neurodegenerative diseases, stroke, traumatic brain injury (TBI), and spinal cord injury. Generally, this hormone decreases neuronal loss and brain edema by down-regulating distinct inflammatory pathways [155–162]. Progesterone typically exerts its actions through progesterone receptors (PRs) such as classical isoforms of PR-A and PR-B which are found in the nucleus and operate as transcription factors via binding to progesterone response elements in the promoter of gene. In addition, progesterone membrane receptors also exist in the brain which transmit a wide variety of progesterone effects [162–165]. Both nuclear and membrane PRs mediate progesterone-regulated responses in the brain affecting directly microglia, astrocytes, and neurons [163]. This hormone can reduce inflammation after cerebral ischemia and TBI via modulating TLR signaling [116, 166]. Hua et al. showed that progesterone did not suppress the activation of TLR2 but rather promoted the




Fig. 4 Effects of neurosteroids on TLR signaling pathways under ischemic conditions. **a** Estrogen/ER could increase I κ B, also ER α could block NF- κ B nuclear translocation. In the nucleus, ER α / β inhibits the expression of TLR2/4, and ER β suppresses the p65 subunit of NF- κ B. Progesterone suppresses LPS-induced NF- κ B activation by prevention of the phosphorylation of I κ B and the p65 subunit. Progesterone also blocks the expression of TLR2/4, increases the expression of I κ B, and TLR9, and suppresses the transcription of the p65 gene. Estrogen/progesterone promote mitochondrial function by blocking of DAMP action and suppressing p38 MAPK activation. **b**

Vitamin D3 binding to VDR leads to anti-inflammatory effects by suppressing phosphorylation of I κ B, p38 MAPK and NF- κ B translocation to the nucleus and also by stimulation of SOCS1 which inhibits the TLR pathway. VD3 exerts a negative regulation of the phosphorylation of I κ B by blocking ROS activity and suppressing the expression of TLR2/4 and NF- κ B activity. Pro-inflammatory effects of VD3 occur via the down-regulation of TLR9 and by blocking of IL-6 expression. Up- and down-regulation of genes are depicted by \uparrow and \downarrow symbols

expression of TLR9 [94, 116]. Furthermore, progesterone and its metabolites regulate TLR4 and NF- κ B signal transduction pathways after subarachnoid hemorrhage and ischemic brain damage [166, 167]. There is more information available concerning the progesterone-mediated control of protective signaling cascades such as inhibition of LPS-induced NF- κ B activation by blocking I κ B α and suppressing p65 subunit phosphorylation, down-regulation of phosphorylation of the p38, JNK and ERK MAPKs in microglia [168], and attenuation of TLR2/4 expression and antagonizing NF- κ B activity by increasing transcription of I κ B α gene or suppression of p65 gene (Fig. 4a) [169, 170]. It has also reported that progesterone controls IL-1 β and TNF- α after TBI [171] and MCAO [172]. However, another report described that progesterone has no influence on the expression of IL-1 β and TNF- α following brain injury [173].

In general, data suggest that a co-treatment of E2 with progesterone is more effective in the treatment of neurodegeneration than exposure to single steroids possibly due to their synergistic effects [174]. A combined EP treatment of cerebral cortex neurons appears to be more effective in preventing glucose serum deprivation (CGSD) and might be the result of direct and indirect interactions with microglia [175–177]. EP treatment also promotes mitochondrial function by attenuating DAMP activity and blocking the TLR4/NF- κ B pathway [176, 178–181].

The negative results of both clinical trials called SyNAPSE and ProTECT III, which used neurosteroids and their derivatives as a treatment regimen created a lot of frustration in the field of steroid-mediated neuroprotection in the brain. The method for administration of progesterone might be one reason for the failure. In the SyNAPSE III and ProTECT trials, natural progesterone has been used by continuous intravenous infusion to patients with TBI. However, none of the preclinical TBI trainings has used this method but instead subcutaneous or intraperitoneal injections [182]. In addition, large doses of progesterone were given in the clinical trials throughout. Only a few animal studies have tried dose–response relationships of progesterone and suggested that high doses of progesterone might be less effective or even damaging after TBI [183]. Furthermore, the abrupt discontinuation of the intravenous progesterone administration and long-term treatment with progesterone after experimental TBI are more effective than a short-term treatment [184, 185]. Therefore, the design of the SyNAPSE and ProTECT III trials could imply some ideal options that were not always supported by existing preclinical outcomes [182].

Vitamin D

Vitamin D3 (cholecalciferol) is mainly synthesized in the skin or is intestinally absorbed. Cholecalciferol can be initially metabolized in the liver into calcifediol (25-hydroxycholecalciferol) and then in the kidney into calcitriol (1,25(OH)₂D₃). Calcitriol is considered the most important biologically active metabolite of vitamin D. It has also been identified as a neuroprotective factor for stroke [126, 186–188]. Vitamin D is structurally similar to classical steroid hormones and mainly acts via nuclear receptors thereby regulating inflammatory genes expressed in macrophages and T lymphocytes [189–191]. Vitamin D can also inhibit inflammatory responses and may elicit anti-inflammatory pathways by acting through specific vitamin D receptors (VDR) [192] which are found in immune cells [193]. There are additional functions of vitamin D along with its influence on immune cells which can be beneficial under pathological conditions including regulation of apoptosis and cell cycle [188]. Calcitriol can also modulate TLR signaling through SOCS1 stimulation, prevent the phosphorylation of p38 MAPK, and inhibit NF- κ B activity (Fig. 4b) [193–197]. I κ B phosphorylation is a result of mitochondrial dysfunction which occurs as a result of an elevation of reactive oxygen species (ROS) in mitochondria of injured cells after hypoxia. It has been suggested that calcitriol/VDR can directly interfere with the I κ B/NF- κ B complex or IKK β , thus preventing the translocation of p65 into the cell nucleus [198, 199]. Treatment of human monocytes and macrophages with vitamin D₃ can also reduce the expression of TLR2/4 and block NF- κ B within the nucleus (Fig. 4b) [200, 201]. Vitamin D₃ can further minimize the release of TNF- α , IL-6, and IL-1b in human/murine macrophages and monocytes following LPS stimulation [201]. Interestingly, TLR2 can promote VDR expression and TLR agonists can elevate the conversion of calcifediol into calcitriol by regulating the expression of 1 α -hydroxylase (1 α OHase) [202, 203]. Recent evidence from animal studies and clinical trials suggest that vitamin D deficiency is correlated with several inflammatory diseases and increased infarct volumes in stroke [193, 204, 205]. Moreover, treatment with vitamin D has been reported to cause TLR9 down-regulation in monocytes and subsequently lower IL-6 release [206]. As well, it has been revealed that co-treatment of vitamin D and progesterone in TBI, an ischemic in vitro neuronal model, and a cerebral ischemia animal model results in better outcomes by modulation of the TLR4/NF- κ B signaling cascade [207, 208].

Conclusion

This review article focused on aspects of TLR signaling during acute neuropathological challenges in the brain and highlighted the potential neuroprotective capacity of estrogen, progesterone and vitamin D3 and their putative interactions with TLR signaling pathways after cerebral ischemia and TBI. In particular, TLR2 and TLR4 signaling appeared to be pivotal for controlling pathogenic immune responses following stroke. All three hormones were able to modulate TLR2 and TLR4 signal transduction. Thus, these steroids and the vitamin can be considered as therapeutic options for stroke therapy.

Acknowledgements This work was supported by a grant (IR.KAUMS.REC. 1395. Grant no. 95086) from Kashan University of Medical Sciences.

Compliance with ethical standards

Conflict of interest The authors declare no conflict of interest.

References

- Gentile NT, McIntosh TK (1993) Antagonists of excitatory amino acids and endogenous opioid peptides in the treatment of experimental central nervous system injury. *Ann Emerg Med* 22:1028–1034
- Moghadam SE, Tameh AA, Vahidinia Z, Atlasi MA, Bafrani HH, Naderian H (2018) Neuroprotective effects of oxytocin hormone after an experimental stroke model and the possible role of Calcipain-1. *J Stroke Cerebrovasc Dis* 27(3):724–732
- Yakovlev AG, Knobloch SM, Fan L, Fox GB, Goodnight R, Faden AI (1997) Activation of CPP32-like caspases contributes to neuronal apoptosis and neurological dysfunction after traumatic brain injury. *J Neurosci* 17:7415–7424
- Iadecola C, Anrather J (2011) The immunology of stroke: from mechanisms to translation. *Nat Med* 17:796–808
- Macrez R, Ali C, Toutirais O, Le Mauff B, Defer G, Dirnagl U et al (2011) Stroke and the immune system: from pathophysiology to new therapeutic strategies. *Lancet Neurol* 10:471–480
- Huang J, Upadhyay UM, Tamargo RJ (2006) Inflammation in stroke and focal cerebral ischemia. *Surg Neurol* 66:232–245
- Wang Y-C, Lin S, Yang Q-W (2011) Toll-like receptors in cerebral ischemic inflammatory injury. *J Neuroinflamm* 8:134
- Crack PJ, Bray PJ (2007) Toll-like receptors in the brain and their potential roles in neuropathology. *Immunol Cell Biol* 85:476–480
- Kaczorowski DJ, Mollen KP, Edmonds R, Billiar TR (2008) Early events in the recognition of danger signals after tissue injury. *J Leukoc Biol* 83:546–552
- Wang Y, Ge P, Zhu Y (2013) TLR2 and TLR4 in the brain injury caused by cerebral ischemia and reperfusion. *Mediat Inflamm* 2013:124614
- Kipp M, Norkute A, Johann S, Lorenz L, Braun A, Hieble A et al (2008) Brain-region-specific astroglial responses in vitro after LPS exposure. *J Mol Neurosci* 35:235–243
- Rivest S (2009) Regulation of innate immune responses in the brain. *Nat Rev Immunol* 9:429–439
- Hornung V, Rothenfusser S, Britsch S, Krug A, Jahrsdörfer B, Giese T et al (2002) Quantitative expression of toll-like receptor 1–10 mRNA in cellular subsets of human peripheral blood mononuclear cells and sensitivity to CpG oligodeoxynucleotides. *J Immunol* 168:4531–4537
- Iwasaki A, Medzhitov R (2004) Toll-like receptor control of the adaptive immune responses. *Nat Immunol* 5:987–995
- Kawai T, Akira S (2010) The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors. *Nat Immunol* 11:373–384
- Matsushima N, Tanaka T, Enkhbayar P, Mikami T, Taga M, Yamada K et al (2007) Comparative sequence analysis of leucine-rich repeats (LRRs) within vertebrate toll-like receptors. *BMC Genom* 8:124
- Roach JC, Glusman G, Rowen L, Kaur A, Purcell MK, Smith KD et al (2005) The evolution of vertebrate Toll-like receptors. *Proc Natl Acad Sci USA* 102:9577–9582
- Gao W, Xiong Y, Li Q, Yang H (2017) Inhibition of toll-like receptor signaling as a promising therapy for inflammatory diseases: a journey from molecular to nano therapeutics. *Front Physiol* 8:508
- Shichita T, Sakaguchi R, Suzuki M, Yoshimura A (2012) Post-ischemic inflammation in the brain. *Front Immunol* 3:132
- Piccinini A, Midwood K (2010) DAMPening inflammation by modulating TLR signalling. *Mediat Inflamm* 2010:672395
- Gürtler C, Bowie AG (2013) Innate immune detection of microbial nucleic acids. *Trends Microbiol* 21:413–420
- Kawasaki T, Kawai T (2014) Toll-like receptor signaling pathways. *Front Immunol* 5:461
- Okun E, Griffioen KJ, Mattson MP (2011) Toll-like receptor signaling in neural plasticity and disease. *Trends Neurosci* 34:269–281
- Buchanan MM, Hutchinson M, Watkins LR, Yin H (2010) Toll-like receptor 4 in CNS pathologies. *J Neurochem* 114:13–27
- Lehnardt S (2010) Innate immunity and neuroinflammation in the CNS: the role of microglia in Toll-like receptor-mediated neuronal injury. *Glia* 58:253–263
- Marsh BJ, Williams-Karnesky RL, Stenzel-Poore MP (2009) Toll-like receptor signaling in endogenous neuroprotection and stroke. *Neuroscience* 158:1007–1020
- Carty M, Bowie AG (2011) Evaluating the role of Toll-like receptors in diseases of the central nervous system. *Biochem Pharmacol* 81:825–837
- Bell JK, Mullen GE, Leifer CA, Mazzoni A, Davies DR, Segal DM (2003) Leucine-rich repeats and pathogen recognition in Toll-like receptors. *Trends Immunol* 24:528–533
- Brodsky I, Medzhitov R (2007) Two modes of ligand recognition by TLRs. *Cell* 130:979–981
- Uematsu S, Akira S (2008) Toll-Like receptors (TLRs) and their ligands. *Handb Exp Pharmacol* 183:1–20
- Botos I, Segal DM, Davies DR (2011) The structural biology of Toll-like receptors. *Structure* 19:447–459
- Flo TH, Halaas O, Torp S, Ryan L et al (2001) Differential expression of Toll-like receptor 2 in human cells. *J Leukoc Biol* 69:474–481
- Bsibsi M, Ravid R, Gveric D, van Noort JM (2002) Broad expression of Toll-like receptors in the human central nervous system. *J Neuropathol Exp Neurol* 61:1013–1021
- Farina C, Krumbholz M, Giese T, Hartmann G et al (2005) Preferential expression and function of Toll-like receptor 3 in human astrocytes. *J Neuroimmunol* 159:12–19
- Rivest S (2003) Molecular insights on the cerebral innate immune system. *Brain Behav Immun* 17:13–19
- Owens T, Babcock AA, Millward JM, Toft-Hansen H (2005) Cytokine and chemokine inter-regulation in the inflamed or injured CNS. *Brain Res Rev* 48:178–184

37. Kielian T (2006) Toll-like receptors in central nervous system glial inflammation and homeostasis. *J Neurosci Res* 83:711–730
38. Jack CS, Arbour N, Manusow J, Montgrain V et al (2005) TLR signaling tailors innate immune responses in human microglia and astrocytes. *J Immunol* 175:4320–4330
39. Rosciszewski G, Cadena V, Murta V et al (2018) Toll-like receptor 4 (TLR4) and triggering receptor expressed on myeloid cells-2 (TREM-2) activation balance astrocyte polarization into a proinflammatory phenotype. *Mol Neurobiol* 55:3875–3888
40. Crocker SJ et al (2008) A novel method to establish microglia-free astrocyte cultures: comparison of matrix metalloproteinase expression profiles in pure cultures of astrocytes and microglia. *Glia* 56:1187–1198
41. Takeda K, Akira S (2005) Toll-like receptors in innate immunity. *Int Immunol* 17:1–14
42. O'Neill LA, Bowie AG (2007) The family of five: TIR-domain-containing adaptors in Toll-like receptor signalling. *Nat Rev Immunol* 7:353–364
43. Akira S, Takeda K (2004) Toll-like receptor signalling. *Nat Rev Immunol* 4:499–511
44. Takeda K, Akira S (eds) (2004) TLR signaling pathways. *Semin Immunol* 16:3–9
45. Akira S, Uematsu S, Takeuchi O (2006) Pathogen recognition and innate immunity. *Cell* 124:783–801
46. Ostuni R, Zanoni I, Granucci F (2010) Deciphering the complexity of Toll-like receptor signaling. *Cell Mol Life Sci* 67:4109–4134
47. Kawagoe T, Sato S, Matsushita K, Kato H, Matsui K, Kumagai Y et al (2008) Sequential control of Toll-like receptor-dependent responses by IRAK1 and IRAK2. *Nat Immunol* 9:684–691
48. Xia Z-P, Sun L, Chen X, Pineda G, Jiang X, Adhikari A et al (2009) Direct activation of protein kinases by unanchored polyubiquitin chains. *Nature* 461:114–119
49. Medzhitov R (2001) Toll-like receptors and innate immunity. *Rev Immunol* 1:135–145
50. Takeuchi O, Akira S (2010) Pattern recognition receptors and inflammation. *Cell* 140:805–820
51. Gujjarro C, Egidio J (2001) Transcription factor- κ B (NF- κ B) and renal disease. *Kidney Int* 59:415–424
52. Nozaki K, Nishimura M, Hashimoto N (2001) Mitogen-activated protein kinases and cerebral ischemia. *Mol Neurobiol* 23:1–19
53. Nito C, Kamada H, Endo H, Narasimhan P, Lee Y-S, Chan PH (2012) Involvement of mitogen-activated protein kinase pathways in expression of the water channel protein aquaporin-4 after ischemia in rat cortical astrocytes. *J Neurotrauma* 29:2404–2412
54. Yasukawa H, Sasaki A, Yoshimura A (2000) Negative regulation of cytokine signaling pathways. *Annu Rev Immunol* 18:143–164
55. Nakagawa R, Naka T, Tsutsui H, Fujimoto M et al (2002) SOCS-1 participates in negative regulation of LPS responses. *Immunity* 17:677–687
56. Yoshimura A, Naka T, Kubo M (2007) SOCS proteins, cytokine signalling and immune regulation. *Nat Rev Immunol* 7:454–465
57. Starczynowski DT, Karsan A (2010) Innate immune signaling in the myelodysplastic syndromes. *Hematol Oncol Clin N Am* 24:343–359
58. Klesney-Tait J, Turnbull IR, Colonna M (2006) The TREM receptor family and signal integration. *Nat Immunol* 7:1266
59. Bouchon A, Dietrich J, Colonna M (2000) Cutting edge: inflammatory responses can be triggered by TREM-1, a novel receptor expressed on neutrophils and monocytes. *J Immunol* 164:4991–4995
60. Nathan C, Ding A (2001) TREM-1: a new regulator of innate immunity in sepsis syndrome. *Nat Med* 7:530
61. Klesney-Tait J, Colonna M (2007) Uncovering the TREM-1-TLR connection. *Am J Physiol Lung Cell Mol Physiol* 293:L1374–L1376
62. Ornatowska M, Azim AC, Wang X, Christman JW et al (2007) Functional genomics of silencing TREM-1 on TLR4 signaling in macrophages. *Am J Physiol Lung Cell Mol Physiol* 293:L1377–L1384
63. Golovkin A, Matveeva VG, Kudryavtsev IV, Chernova MN et al (2013) Perioperative dynamics of TLR2, TLR4, and TREM-1 expression in monocyte subpopulations in the setting of on-pump coronary artery bypass surgery. *ISRN Inflamm* 2013:817901
64. Marsh BJ, Stenzel-Poore MP (2008) Toll-like receptors: novel pharmacological targets for the treatment of neurological diseases. *Curr Opin Pharmacol* 8:8–13
65. Marsh BJ, Stevens SL, Hunter B, Stenzel-Poore MP (2009) Inflammation and the emerging role of the toll-like receptor system in acute brain ischemia. *Stroke* 40:S34–S37
66. Tang S-C, Arumugam TV, Xu X, Cheng A, Mughal MR, Jo DG et al (2007) Pivotal role for neuronal Toll-like receptors in ischemic brain injury and functional deficits. *Proc Natl Acad Sci* 104:13798–13803
67. Chen S, Wong MH, Schulte DJ, Arditi M, Michelsen KS (2007) Differential expression of Toll-like receptor 2 (TLR2) and responses to TLR2 ligands between human and murine vascular endothelial cells. *J Endotoxin Res* 13:281–296
68. Ziegler G, Harhausen D, Schepers C, Hoffmann O, Röhr C, Prinz V et al (2007) TLR2 has a detrimental role in mouse transient focal cerebral ischemia. *Biochem Biophys Res Commun* 359:574–579
69. Ziegler G, Freyer D, Harhausen D, Khojasteh U, Nietfeld W, Trendelenburg G (2011) Blocking TLR2 in vivo protects against accumulation of inflammatory cells and neuronal injury in experimental stroke. *J Cereb Blood Flow Metab* 31:757–766
70. Yang Q-W, Lu F-L, Zhou Y, Wang L, Zhong Q, Lin S et al (2011) HMGB1 mediates ischemia–reperfusion injury by TRIF-adaptor independent toll-like receptor 4 signaling. *J Cereb Blood Flow Metab* 31:593–605
71. Yang Q-W, Wang J-Z, Li J-C, Zhou Y, Qi-Zhong LuF-L et al (2010) High-mobility group protein box-1 and its relevance to cerebral ischemia. *J Cereb Blood Flow Metab* 30:243–254
72. Qiu J, Nishimura M, Wang Y, Sims JR, Qiu S, Savitz SI et al (2008) Early release of HMGB-1 from neurons after the onset of brain ischemia. *J Cereb Blood Flow Metab* 28:927–938
73. Muhammad S, Barakat W, Stoyanov S, Murikinati S, Yang H, Tracey KJ et al (2008) The HMGB1 receptor RAGE mediates ischemic brain damage. *J Neurosci* 28:12023–12031
74. Liu K, Mori S, Takahashi HK, Tomono Y, Wake H, Kanke T et al (2007) Anti-high mobility group box 1 monoclonal antibody ameliorates brain infarction induced by transient ischemia in rats. *FASEB J* 21:3904–3916
75. Patenaude A, Murthy M, Mirault M-E (2005) Emerging roles of thioredoxin cycle enzymes in the central nervous system. *Cell Mol Life Sci CMLS* 62:1063–1080
76. Rashidian J, Rousseaux MW, Venderova K, Qu D, Callaghan SM, Phillips M et al (2009) Essential role of cytoplasmic cdk5 and Prx2 in multiple ischemic injury models, in vivo. *J Neurosci* 29:12497–12505
77. Lehnardt S, Lehmann S, Kaul D, Tschimmel K, Hoffmann O, Cho S et al (2007) Toll-like receptor 2 mediates CNS injury in focal cerebral ischemia. *J Neuroimmunol* 190:28–33
78. Lv M, Liu Y, Zhang J, Sun L, Liu Z, Zhang S et al (2011) Roles of inflammation response in microglia cell through Toll-like receptors 2/interleukin-23/interleukin-17 pathway in cerebral ischemia/reperfusion injury. *Neuroscience* 176:162–172

79. Abe T, Shimamura M, Jackman K, Kurinami H, Anrather J, Zhou P et al (2010) Key role of CD36 in Toll-like receptor 2 signaling in cerebral ischemia. *Stroke* 41:898–904
80. Brea D, Sobrino T, Rodríguez-Yáñez M, Ramos-Cabrer P, Agulla J, Rodríguez-González R et al (2011) Toll-like receptors 7 and 8 expression is associated with poor outcome and greater inflammatory response in acute ischemic stroke. *Clin Immunol* 139:193–198
81. Hyakkoku K, Hamanaka J, Tsuruma K, Shimazawa M, Tanaka H, Uematsu S et al (2010) Toll-like receptor 4 (TLR4), but not TLR3 or TLR9, knock-out mice have neuroprotective effects against focal cerebral ischemia. *Neuroscience* 171:258–267
82. Alexopoulou L, Holt AC, Medzhitov R, Flavell RA (2001) Recognition of double-stranded RNA and activation of NF- κ B by Toll-like receptor 3. *Nature* 413:732–738
83. Cameron JS, Alexopoulou L, Sloane JA, DiBernardo AB, Ma Y, Kosaras B et al (2007) Toll-like receptor 3 is a potent negative regulator of axonal growth in mammals. *J Neurosci* 27:13033–13041
84. Okun E, Griffioen K, Barak B, Roberts NJ, Castro K, Pita MA et al (2010) Toll-like receptor 3 inhibits memory retention and constrains adult hippocampal neurogenesis. *Proc Natl Acad Sci* 107:15625–15630
85. Wang P-F, Xiong X-Y, Chen J, Wang Y-C, Duan W, Yang Q-W (2015) Function and mechanism of toll-like receptors in cerebral ischemic tolerance: from preconditioning to treatment. *J Neuro-inflamm* 12:80
86. Hayakawa K, Qiu J, Lo EH (2010) Biphasic actions of HMGB1 signaling in inflammation and recovery after stroke. *Ann N Y Acad Sci* 1207:50–57
87. Gelderblom M, Leyboldt F, Steinbach K, Behrens D, Choe C-U, Siler DA et al (2009) Temporal and spatial dynamics of cerebral immune cell accumulation in stroke. *Stroke* 40:1849–1857
88. Zhang J, Takahashi HK, Liu K, Wake H, Liu R, Maruo T et al (2011) Anti-high mobility group box-1 monoclonal antibody protects the blood–brain barrier from ischemia-induced disruption in rats. *Stroke* 42:1420–1428
89. C-x Cao, Q-w Yang, F-l Lv, Cui J, H-b Fu, J-z Wang (2007) Reduced cerebral ischemia-reperfusion injury in Toll-like receptor 4 deficient mice. *Biochem Biophys Res Commun* 353:509–514
90. Caso JR, Pradillo JM, Hurtado O, Lorenzo P, Moro MA, Lizasoain I (2007) Toll-like receptor 4 is involved in brain damage and inflammation after experimental stroke. *Circulation* 115:1599–1608
91. Tang S-C, Lathia JD, Selvaraj PK, Jo D-G, Mughal MR, Cheng A et al (2008) Toll-like receptor-4 mediates neuronal apoptosis induced by amyloid β -peptide and the membrane lipid peroxidation product 4-hydroxynonenal. *Exp Neurol* 213:114–121
92. Caso JR, Pradillo JM, Hurtado O, Leza JC, Moro MA, Lizasoain I (2008) Toll-like receptor 4 is involved in subacute stress-induced neuroinflammation and in the worsening of experimental stroke. *Stroke* 39:1314–1320
93. Kilic U, Kilic E, Matter CM, Bassetti CL, Hermann DM (2008) TLR-4 deficiency protects against focal cerebral ischemia and axotomy-induced neurodegeneration. *Neurobiol Dis* 31:33–40
94. Stevens SL, Ciesielski TM, Marsh BJ, Yang T, Homen DS, Boule J-L et al (2008) Toll-like receptor 9: a new target of ischemic preconditioning in the brain. *J Cereb Blood Flow Metab* 28:1040–1047
95. Nalamolu KR, Smith NJ, Chelluboina B, Klopfenstein JD et al (2018) Prevention of the severity of post-ischemic inflammation and brain damage by simultaneous knockdown of Toll-like receptors 2 and 4. *Neuroscience* 373:82–91
96. Song Y, Liu H, Long L, Zhang N, Liu Y (2015) TLR4 rs1927911, but not TLR2 rs5743708, is associated with atherosclerotic cerebral infarction in the Southern Han population: a case–control study. *Medicine* 94:e381
97. Lin Y-C, Chang Y-M, Yu J-M, Yen J-H, Chang J-G, Hu C-J (2005) Toll-like receptor 4 gene C119A but not Asp299Gly polymorphism is associated with ischemic stroke among ethnic Chinese in Taiwan. *Atherosclerosis* 180:305–309
98. Ioana M, Ferwerda B, Plantinga T, Stappers M, Oosting M, McCall M et al (2012) Different patterns of Toll-like receptor 2 polymorphisms in populations of various ethnic and geographic origins. *Infect Immun* 80:1917–1922
99. Zhou L, Zheng D, Wang S, Zhu J, Jia Y, Sun D et al (2016) Genetic association of Toll-like receptor 4 gene and coronary artery disease in a Chinese Han population. *SpringerPlus* 5:1533
100. Ebrahimi A, Colagar AH, Karimian M (2017) Association of human methionine synthase-A2756G transition with prostate cancer: a case–control study and in silico analysis. *Acta Med Iran* 55:297–303
101. Zamani-Badi T, Nikzad H, Karimian M (2018) IL-1RA VNTR and IL-1 α 4845G > T polymorphisms and risk of idiopathic male infertility in Iranian men: a case–control study and an in silico analysis. *Andrologia* 3:e13081
102. Sabarinathan R, Tafer H, Seemann SE, Hofacker IL, Stadler PF, Gorodkin J (2013) RNAsnp: efficient detection of local RNA secondary structure changes induced by SNPs. *Hum Mutat* 34:546–556
103. Zamani-Badi T, Karimian M, Azami-Tameh A, Nikzad H (2017) Association of C3953T transition in interleukin 1 β gene with idiopathic male infertility in an Iranian population. *Hum Fertil* 3:1–7
104. Karimian M, Aftabi Y, Mazoochi T, Babaei F et al (2018) Survivin polymorphisms and susceptibility to prostate cancer: a genetic association study and an in silico analysis. *EXCLI J* 17:479
105. Salimi S, Keshavarzi F, Mohammadpour-Gharehbagh A, Moodi M et al (2017) Polymorphisms of the folate metabolizing enzymes: association with SLE susceptibility and in silico analysis. *Gene* 637:161–172
106. Tameh AA, Karimian M, Zare-Dehghanani Z, Aftabi Y et al (2018) Role of steroid therapy after ischemic stroke by *N*-methyl-D-aspartate receptor gene regulation. *J Stroke Cerebrovasc Dis* 27:3066–3075
107. Nejati M, Atlasi MA, Karimian M, Nikzad H et al (2018) Lipoprotein lipase gene polymorphisms as risk factors for stroke: a computational and meta-analysis. *Iran J Basic Med Sci* 21:701–708
108. Reumers J, Schymkowitz J, Ferkinghoff-Borg J, Stricher F, Serrano L, Rousseau F (2005) SNPeff: a database mapping molecular phenotypic effects of human non-synonymous coding SNPs. *Nucleic Acids Res* 33:D527–D532
109. Adzhubei IA, Schmidt S, Peshkin L, Ramensky VE, Gerasimova A, Bork P et al (2010) A method and server for predicting damaging missense mutations. *Nat Methods* 7:248–249
110. Bromberg Y, Rost B (2007) SNAP: predict effect of non-synonymous polymorphisms on function. *Nucleic Acids Res* 35:3823–3835
111. Kumar P, Henikoff S, Ng PC (2009) Predicting the effects of coding non-synonymous variants on protein function using the SIFT algorithm. *Nat Protoc* 4:1073–1081
112. De Baets G, Van Durme J, Reumers J, Maurer-Stroh S, Vanhee P, Dopazo J et al (2011) SNPeff 4.0: on-line prediction of molecular and structural effects of protein-coding variants. *Nucleic Acids Res* 40:D935–D939

113. Capriotti E, Calabrese R, Fariselli P, Martelli PL, Altman RB, Casadio R (2013) WS-SNPs&GO: a web server for predicting the deleterious effect of human protein variants using functional annotation. *BMC Genom* 14:S6
114. Compagnone NA, Mellon SH (2000) Neurosteroids: biosynthesis and function of these novel neuromodulators. *Front Neuroendocrinol* 21:1–56
115. Rupprecht R, Holsboer F (1999) Neuroactive steroids: mechanisms of action and neuropsychopharmacological perspectives. *Trends Neurosci* 22:410–416
116. Hua F, Wang J, Ishrat T, Wei W, Atif F, Sayeed I et al (2011) Genomic profile of Toll-like receptor pathways in traumatically brain-injured mice: effect of exogenous progesterone. *J Neuroinflamm* 8:42
117. Lobo RA, Pinkerton JV, Gass ML, Dorin MH, Ronkin S, Pickar JH et al (2009) Evaluation of bazedoxifene/conjugated estrogens for the treatment of menopausal symptoms and effects on metabolic parameters and overall safety profile. *Fertil Steril* 92:1025–1038
118. Carwile E, Wagner AK, Crago E, Alexander SA (2009) Estrogen and stroke: a review of the current literature. *J Neurosci Nurs* 41:18–25
119. Roof RL, Hall ED (2000) Gender differences in acute CNS trauma and stroke: neuroprotective effects of estrogen and progesterone. *J Neurotrauma* 17:367–388
120. Baulieu E-E, Schumacher M (2000) Progesterone as a neuroactive neurosteroid, with special reference to the effect of progesterone on myelination. *Steroids* 65:605–612
121. Johann S, Beyer C (2013) Neuroprotection by gonadal steroid hormones in acute brain damage requires cooperation with astroglia and microglia. *J Steroid Biochem Mol Biol* 137:71–81
122. Ritzel RM, Capozzi LA, McCullough LD (2013) Sex, stroke, and inflammation: the potential for estrogen-mediated immunoprotection in stroke. *Horm Behav* 63:238–253
123. Suzuki S, Brown CM, Wise PM (2009) Neuroprotective effects of estrogens following ischemic stroke. *Front Neuroendocrinol* 30:201–211
124. Zhang Q-G, Raz L, Wang R, Han D, De Sevilla L, Yang F et al (2009) Estrogen attenuates ischemic oxidative damage via an estrogen receptor α -mediated inhibition of NADPH oxidase activation. *J Neurosci* 29:13823–13836
125. Herson PS, Koerner IP, Hurn PD (2009) Sex, sex steroids, and brain injury. *Semin Reprod Med* 27:229–239
126. Fu J, Xue R, Gu J, Xiao Y, Zhong H, Pan X et al (2013) Neuroprotective effect of calcitriol on ischemic/reperfusion injury through the NR3A/CREB pathways in the rat hippocampus. *Mol Med Rep* 8:1708–1714
127. Brewer LD, Thibault V, Chen K-C, Langub MC, Landfield PW, Porter NM (2001) Vitamin D hormone confers neuroprotection in parallel with downregulation of L-type calcium channel expression in hippocampal neurons. *J Neurosci* 21:98–108
128. Kalueff A, Eremin K, Tuohimaa P (2004) Mechanisms of neuroprotective action of vitamin D3. *Biochemistry (Moscow)* 69:738–741
129. Manthey D, Behl C (2006) From structural biochemistry to expression profiling: neuroprotective activities of estrogen. *Neuroscience* 138:845–850
130. Strom JO, Theodorsson A, Theodorsson E (2009) Dose-related neuroprotective versus neurodamaging effects of estrogens in rat cerebral ischemia: a systematic analysis. *J Cereb Blood Flow Metab* 29:1359–1372
131. Strom JO, Theodorsson A, Theodorsson E (2011) Mechanisms of estrogens' dose-dependent neuroprotective and neurodamaging effects in experimental models of cerebral ischemia. *Int J Mol Sci* 12:1533–1562
132. Kipp M, Karakaya S, Pawlak J, Araujo-Wright G, Arnold S, Beyer C (2006) Estrogen and the development and protection of nigrostriatal dopaminergic neurons: concerted action of a multitude of signals, protective molecules, and growth factors. *Front Neuroendocrinol* 27:376–390
133. Zhang Q-G, Wang R, Tang H, Dong Y, Chan A, Sareddy GR et al (2014) Brain-derived estrogen exerts anti-inflammatory and neuroprotective actions in the rat hippocampus. *Mol Cell Endocrinol* 389:84–91
134. Jover-Mengual T, Castelló-Ruiz M, Burguete MC, Jorques M, López-Morales MA, Aliena-Valero A et al (2017) Molecular mechanisms mediating the neuroprotective role of the selective estrogen receptor modulator, bazedoxifene, in acute ischemic stroke: a comparative study with 17 β -estradiol. *J Steroid Biochem Mol Biol* 171:296–304
135. Gibson CL, Gray LJ, Murphy SP, Bath PM (2006) Estrogens and experimental ischemic stroke: a systematic review. *J Cereb Blood Flow Metab* 26:1103–1113
136. Scharfman HE, MacLusky NJ (2006) Estrogen and brain-derived neurotrophic factor (BDNF) in hippocampus: complexity of steroid hormone-growth factor interactions in the adult CNS. *Front Neuroendocrinol* 27:415–435
137. Marks MA, Gravitt PE, Burk RD, Studentsov Y, Farzadegan H, Klein SL (2010) Progesterone and 17 β -estradiol enhance regulatory responses to human papillomavirus type 16 virus-like particles in peripheral blood mononuclear cells from healthy women. *Clin Vaccine Immunol* 17:609–617
138. Lakhan SE, Kirchgessner A, Hofer M (2009) Inflammatory mechanisms in ischemic stroke: therapeutic approaches. *J Transl Med* 7:97
139. Xu Y, Sheng H, Bao Q, Wang Y, Lu J, Ni X (2016) NLRP3 inflammasome activation mediates estrogen deficiency-induced depression-and anxiety-like behavior and hippocampal inflammation in mice. *Brain Behav Immun* 56:175–186
140. Cordeau P, Lalancette-Hébert M, Weng YC, Kriz J (2016) Estrogen receptors α mediates postischemic inflammation in chronically estrogen-deprived mice. *Neurobiol Aging* 40:50–60
141. Behl C (2002) Oestrogen as a neuroprotective hormone. *Nat Rev Neurosci* 3:433–442
142. Dubal DB, Rau SW, Shughue PJ, Zhu H, Yu J, Cashion AB et al (2006) Differential modulation of estrogen receptors (ERs) in ischemic brain injury: a role for ER α in estradiol-mediated protection against delayed cell death. *Endocrinology* 147:3076–3084
143. Rusa R, Alkayed NJ, Crain BJ, Traystman RJ, Kimes AS, London ED et al (1999) 17 β -Estradiol reduces stroke injury in estrogen-deficient female animals. *Stroke* 30:1665–1670
144. Kurebayashi S, Miyashita Y, Hirose T, Kasayama S, Akira S, Kishimoto T (1997) Characterization of mechanisms of interleukin-6 gene repression by estrogen receptor. *J Steroid Biochem Mol Biol* 60:11–17
145. Stein B, Yang MX (1995) Repression of the interleukin-6 promoter by estrogen receptor is mediated by NF-kappa B and C/EBP beta. *Mol Cell Biol* 15:4971–4979
146. Ghisletti S, Meda C, Maggi A, Vegeto E (2005) 17 β -estradiol inhibits inflammatory gene expression by controlling NF-kB intracellular localization. *Mol Cell Biol* 25:2957–2968
147. Koellhoffer EC, McCullough LD (2013) The effects of estrogen in ischemic stroke. *Transl Stroke Res* 4:390–401
148. Liao SL, Chen WY, Chen CJ (2002) Estrogen attenuates tumor necrosis factor- α expression to provide ischemic neuroprotection in female rats. *Neurosci Lett* 330:159–162
149. Wen Y, Yang S, Liu R, Perez E, Yi KD, Koulen P et al (2004) Estrogen attenuates nuclear factor-kappa B activation induced by transient cerebral ischemia. *Brain Res* 1008:147–154
150. Calippe B, Douin-Echinard V, Laffargue M, Laurell H, Rana-Poussine V, Pipy B et al (2008) Chronic estradiol administration

- in vivo promotes the proinflammatory response of macrophages to TLR4 activation: involvement of the phosphatidylinositol 3-kinase pathway. *J Immunol* 180:7980–7988
151. Chiappetta O, Gliozzi M, Siviglia E, Amantea D, Morrone LA, Berliocchi L et al (2007) Evidence to implicate early modulation of interleukin-1 β expression in the neuroprotection afforded by 17 β -estradiol in male rats undergone transient middle cerebral artery occlusion. *Int Rev Neurobiol* 82:357–372
 152. Petrone AB, Simpkins JW, Barr TL (2014) 17 β -Estradiol and inflammation: implications for ischemic stroke. *Aging Dis* 5:340–345
 153. Dominguez R, Liu R, Baudry M (2007) 17- β -Estradiol-mediated activation of extracellular-signal regulated kinase, phosphatidylinositol 3-kinase/protein kinase B-Akt and *N*-methyl-D-aspartate receptor phosphorylation in cortical synaptoneurosome. *J Neurochem* 101:232–240
 154. Pinceti E (2016) Consequences of estrogen receptor beta phosphorylation in the aged female brain and heart. Loyola University Chicago, Chicago
 155. Stein DG (2013) A clinical/translational perspective: can a developmental hormone play a role in the treatment of traumatic brain injury? *Horm Behav* 63:291–300
 156. Wright DW, Bauer ME, Hoffman SW, Stein DG (2001) Serum progesterone levels correlate with decreased cerebral edema after traumatic brain injury in male rats. *J Neurotrauma* 18:901–909
 157. O'Connor CA, Cernak I, Vink R (2005) Both estrogen and progesterone attenuate edema formation following diffuse traumatic brain injury in rats. *Brain Res* 1062:171–174
 158. Pettus EH, Wright DW, Stein DG, Hoffman SW (2005) Progesterone treatment inhibits the inflammatory agents that accompany traumatic brain injury. *Brain Res* 1049:112–119
 159. Guo Q, Sayeed I, Baronne LM, Hoffman SW, Guennoun R, Stein DG (2006) Progesterone administration modulates AQP4 expression and edema after traumatic brain injury in male rats. *Exp Neurol* 198:469–478
 160. Leonelli E, Bianchi R, Cavaletti G, Caruso D, Crippa D, Garcia-Segura L et al (2007) Progesterone and its derivatives are neuroprotective agents in experimental diabetic neuropathy: a multimodal analysis. *Neuroscience* 144:1293–1304
 161. VanLandingham JW, Cekic M, Cutler SM, Hoffman SW, Washington ER, Johnson SJ et al (2008) Progesterone and its metabolite allopregnanolone differentially regulate hemostatic proteins after traumatic brain injury. *J Cereb Blood Flow Metab* 28:1786–1794
 162. Loane DJ, Faden AI (2010) Neuroprotection for traumatic brain injury: translational challenges and emerging therapeutic strategies. *Trends Pharmacol Sci* 31:596–604
 163. Brinton RD, Thompson RF, Foy MR, Baudry M, Wang J, Finch CE et al (2008) Progesterone receptors: form and function in brain. *Front Neuroendocrinol* 29:313–339
 164. Mani S (2008) Progesterone receptor subtypes in the brain: the known and the unknown. *Endocrinology* 149:2750–2756
 165. Singh M, Su C (2013) Progesterone and neuroprotection. *Horm Behav* 63:284–290
 166. Li X, Zhang J, Zhu X, Wang P, Wang X, Li D (2015) Progesterone reduces inflammation and apoptosis in neonatal rats with hypoxic ischemic brain damage through the PI3K/Akt pathway. *Int J Clin Exp Med* 8:8197–8203
 167. Wang Z, Zuo G, Shi X-Y, Zhang J, Fang Q, Chen G (2011) Progesterone administration modulates cortical TLR4/NF- κ B signaling pathway after subarachnoid hemorrhage in male rats. *Mediat Inflamm* 2011:848309
 168. Lei B, Mace B, Dawson HN, Warner DS, Laskowitz DT, James ML (2014) Anti-inflammatory effects of progesterone in lipopolysaccharide-stimulated BV-2 microglia. *PLoS One* 9:e103969
 169. Chen G, Shi J, Jin W, Wang L, Xie W, Sun J et al (2008) Progesterone administration modulates TLR4/NF- κ B signaling pathway in rat brain after cortical contusion. *Ann Clin Lab Sci* 38:65–74
 170. Hardy DB, Janowski BA, Chen C-C, Mendelson CR (2008) Progesterone receptor inhibits aromatase and inflammatory response pathways in breast cancer cells via ligand-dependent and ligand-independent mechanisms. *Mol Endocrinol* 22:1812–1824
 171. He J, Evans C-O, Hoffman SW, Oyesiku NM, Stein DG (2004) Progesterone and allopregnanolone reduce inflammatory cytokines after traumatic brain injury. *Exp Neurol* 189:404–412
 172. Ishrat T, Sayeed I, Atif F, Hua F, Stein DG (2010) Progesterone and allopregnanolone attenuate blood–brain barrier dysfunction following permanent focal ischemia by regulating the expression of matrix metalloproteinases. *Exp Neurol* 226:183–190
 173. Jones NC, Constantin D, Prior MJ, Morris PG, Marsden CA, Murphy S (2005) The neuroprotective effect of progesterone after traumatic brain injury in male mice is independent of both the inflammatory response and growth factor expression. *Eur J Neurosci* 21:1547–1554
 174. Toung TJ, Chen T-Y, Littleton-Kearney MT, Hurn PD, Murphy SJ (2004) Effects of combined estrogen and progesterone on brain infarction in reproductively senescent female rats. *J Cereb Blood Flow Metab* 24:1160–1166
 175. Lorenz L, Dang J, Misiak M, Tameh Abolfazl A, Beyer C, Kipp M (2009) Combined 17 β -oestradiol and progesterone treatment prevents neuronal cell injury in cortical but not midbrain neurons or neuroblastoma cells. *J Neuroendocrinol* 21:841–849
 176. Habib P, Dang J, Slowik A, Victor M, Beyer C (2014) Hypoxia-induced gene expression of aquaporin-4, cyclooxygenase-2 and hypoxia-inducible factor 1 α in rat cortical astroglia is inhibited by 17 β -estradiol and progesterone. *Neuroendocrinology* 99:156–167
 177. Dang J, Mitkari B, Kipp M, Beyer C (2011) Gonadal steroids prevent cell damage and stimulate behavioral recovery after transient middle cerebral artery occlusion in male and female rats. *Brain Behav Immun* 25:715–726
 178. Vahidinia Z, Alipour N, Atlasi MA, Naderian H, Beyer C, Azami Tameh A (2017) Gonadal steroids block the calpain-1-dependent intrinsic pathway of apoptosis in an experimental rat stroke model. *Neurol Res* 39:54–64
 179. Slowik A, Beyer C (2015) Inflammasomes are neuroprotective targets for sex steroids. *J Steroid Biochem Mol Biol* 153:135–143
 180. Lammerding L, Slowik A, Johann S, Beyer C, Zendedel A (2016) Poststroke inflammasome expression and regulation in the perinfarct area by gonadal steroids after transient focal ischemia in the rat brain. *Neuroendocrinology* 103:460–475
 181. Hoffmann S, Beyer C, Zendedel A (2015) Comparative analysis of gonadal steroid-mediated neuroprotection after transient focal ischemia in rats: route of application and substrate composition. *J Mol Neurosci* 56:12–16
 182. Schumacher M, Denier C, Oudinet JP, Adams D et al (2016) Progesterone neuroprotection: the background of clinical trial failure. *J Steroid Biochem Mol Biol* 160:53–66
 183. Goss CW, Hoffman SW, Stein DG (2003) Behavioral effects and anatomic correlates after brain injury: a progesterone dose-response study. *Pharmacol Biochem Behav* 76:231–242
 184. Galani R, Hoffman SW, Stein DG (2001) Effects of the duration of progesterone treatment on the resolution of cerebral edema induced by cortical contusions in rats. *Restor Neurol Neurosci* 18:161–166
 185. Shear DA, Galani R, Hoffman SW, Stein DG (2002) Progesterone protects against necrotic damage and behavioral abnormalities caused by traumatic brain injury. *Exp Neurol* 178:59–67
 186. Eelen G, Verlinden L, Van Camp M, Van Hummelen P, Marchal K, De Moor B et al (2004) The effects of 1 α ,

- 25-dihydroxyvitamin D3 on the expression of DNA replication genes. *J Bone Miner Res* 19:133–146
187. Baekke F, Takiishi T, Korf H, Gysemans C, Mathieu C (2010) Vitamin D: modulator of the immune system. *Curr Opin Pharmacol* 10:482–496
188. Yuan J, Guo X, Liu Z, Zhao X, Feng Y, Song S et al (2018) Vitamin D receptor activation influences the ERK pathway and protects against neurological deficits and neuronal death. *Int J Mol Med* 41:364–372
189. Farach-Carson MC, Nemere I (2003) Membrane receptors for vitamin D steroid hormones: potential new drug targets. *Curr Drug Targets* 4:67–76
190. De Bosscher K, Vanden Berghe W, Haegeman G (2006) Cross-talk between nuclear receptors and nuclear factor kappaB. *Oncogene* 25:6868–6886
191. Norman AW, Nemere I, Zhou L-X, Bishop JE, Lowe KE, Maiyar AC et al (1992) 1,25 (OH) 2-vitamin D3, a steroid hormone that produces biologic effects via both genomic and nongenomic pathways. *J Steroid Biochem Mol Biol* 41:231–240
192. Calton EK, Keane KN, Newsholme P, Soares MJ (2015) The impact of vitamin D levels on inflammatory status: a systematic review of immune cell studies. *PLoS One* 10:e0141770
193. Yin K, Agrawal DK (2014) Vitamin D and inflammatory diseases. *J Inflamm Res* 7:69–87
194. Chen Y, Zhang J, Ge X, Du J, Deb DK, Li YC (2013) Vitamin D receptor inhibits nuclear factor kappaB activation by interacting with Ikb kinase beta protein. *J Biol Chem* 288:19450–19458
195. Vuolo L, Di Somma C, Faggiano A, Colao A (2012) Vitamin D and cancer. *Front Endocrinol (Lausanne)* 3:58
196. Sanchez-Niño M-D, Bozic M, Córdoba-Lanús E, Valcheva P, Gracia O, Ibarz M et al (2011) Beyond proteinuria: VDR activation reduces renal inflammation in experimental diabetic nephropathy. *Am J Physiol Renal Physiol* 302:F647–F657
197. Mutt SJ, Hyppönen E, Saarnio J, Järvelin M-R, Herzig K-H (2014) Vitamin D and adipose tissue—more than storage. *Front Physiol* 5:228
198. Won S, Sayeed I, Peterson BL, Wali B, Kahn JS, Stein DG (2015) Vitamin D prevents hypoxia/reoxygenation-induced blood-brain barrier disruption via vitamin D receptor-mediated NF-kB signaling pathways. *PLoS One* 10:e0122821
199. Chen Y, Liu W, Sun T, Huang Y, Wang Y, Deb DK et al (2013) 1,25-Dihydroxyvitamin D promotes negative feedback regulation of TLR signaling via targeting MicroRNA-155–SOCS1 in macrophages. *J Immunol* 190:3687–3695
200. Sadeghi K, Wessner B, Laggner U, Ploder M, Tamandl D, Friedl J et al (2006) Vitamin D3 down-regulates monocyte TLR expression and triggers hyporesponsiveness to pathogen-associated molecular patterns. *Eur J Immunol* 36:361–370
201. Di Rosa M, Malaguarnera G, De Gregorio C, Palumbo M, Nunnari G, Malaguarnera L (2012) Immuno-modulatory effects of vitamin D3 in human monocyte and macrophages. *Cell Immunol* 280:36–43
202. Kamen DL, Tangpricha V (2010) Vitamin D and molecular actions on the immune system: modulation of innate and autoimmunity. *J Mol Med* 88:441–450
203. Kawai T, Akira S (eds) (2007) TLR signaling. *Semin Immunol* 19:24–32
204. Turetsky A, Goddeau RP, Henninger N (2015) Low serum vitamin D is independently associated with larger lesion volumes after ischemic stroke. *J Stroke Cerebrovasc Dis* 24:1555–1563
205. Balden R, Selvamani A, Sohrabji F (2012) Vitamin D deficiency exacerbates experimental stroke injury and dysregulates ischemia-induced inflammation in adult rats. *Endocrinology* 153:2420–2435
206. Dickie LJ, Church LD, Coulthard LR, Mathews RJ, Emery P, McDermott MF (2010) Vitamin D3 down-regulates intracellular Toll-like receptor 9 expression and Toll-like receptor 9-induced IL-6 production in human monocytes. *Rheumatology* 49:1466–1471
207. Tang H, Hua F, Wang J, Yousuf S, Atif F, Sayeed I et al (2015) Progesterone and vitamin D combination therapy modulates inflammatory response after traumatic brain injury. *Brain Inj* 17:1–10
208. Atif F, Yousuf S, Sayeed I, Ishrat T, Hua F, Stein DG (2013) Combination treatment with progesterone and vitamin D hormone is more effective than monotherapy in ischemic stroke: the role of BDNF/TrkB/Erk1/2 signaling in neuroprotection. *Neuropharmacology* 67:78–87